Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Amarex Clinical Research guides its client to phase II of FDA trials
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Subscribe To Our Newsletter & Stay Updated
